"The summary includes remarks by FTC Chair Lina Khan, questioning whether additional considerations beyond traditional horizontal overlap theories should be analyzed when evaluating deals in the pharmaceutical context -- including more closely examining remedies, potential innovation and prior bad acts by the parties to a deal.... The topics discussed broadly fell into several categories ... [1] concentration in the pharmaceutical industry, [2] remedies in pharmaceutical mergers, and [3] examination of prior bad acts in merger review. This article discusses and analyzes these topics."

MORE >>